Valeant Pharma (VRX) Misses Q2 EPS by 10c; Boosts FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil falls 1% as investors watch Middle East supply disruptions
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Valeant Pharmaceuticals Reports Second Quarter 2015 Financial Results
July 23, 2015 6:00 AM EDTLAVAL, Quebec, July 23, 2015 /PRNewswire/ --
2015 Second Quarter Results
Total Revenue $2.7 billion; an increase of 34% over the prior year Excluding negative impact of foreign exchange ($173 million) and the contribution of Salix ($313 million), revenue increased 27% over the prior year Same Store Sales Organic Growth was 19%, driven by: U.S. businesses, driven by the strength of dermatology, contact lenses, dental and Obagi Emerging markets including China, the Middle East/North Africa, and Russia GAAP EPS Loss of... More